Introduction of escitalopram, a new SSRI in Finland: comparison of cost-effectiveness between the other SSRIs and SNRI for the treatment of depression and estimation of the budgetary impact

References

• CCOHTA. Guidelines for economic evaluation of pharmaceuticals: Canada. 2nd edn. 1997; Ottawa, Canadian Coordinating Office for Health Technology Assessment (CCOHTA).
   Google Scholar
• Finnish Pharmaceuticals Pricing Board. Guidelines for the Preparation of an account of health-economic aspects (an unofficial translation). 1999.
   Google Scholar
• Einarson TR, Arikian S, Sweeney S et al. A model to evaluate the cost- effectiveness of oral therapies in the management of patients with major depressive disorders. Clinical Therapeutics 1995; 17: 136–153.
   Google Scholar
• Lapierre Y, Bentkover J, Schainbaum, S et al. Direct cost of depression: analysis of treatment costs of paroxetine versus Imipramine in Canada. Canadian Journal of Psychiatry 1995; 40: 370–377.
   PubMed Web of Science ®Google Scholar
• Nuijten MJ, Hardens M, Souetre E. A Markov process analysis comparing the cost effectiveness of maintenance therapy with citalopram versus standard therapy in major depression. Pharmacoeconomics 1995; 8: 159–168.
   PubMed Web of Science ®Google Scholar
• Einarson TR, Addis A, Iskedjian M. Pharmacoeconomic analysis of venlafaxine in the treatment of major depressive disorder. Pharmacoeconomics 1997; 12: 286–296.
   PubMed Web of Science ®Google Scholar
• Buxton MJ, Drummond MF, Van Hout BA et al. Modelling in economic evaluation: an unavoidable fact of life [editorial] [see comments]. Health Economics 1997; 6: 217–227.
   PubMed Web of Science ®Google Scholar
• Practice guideline for the treatment of patients with major depressive disorder (revision). American Journal of Psychiatry 2000; 157 (Suppl): 1–45.
   Web of Science ®Google Scholar
• Anderson IM, Nutt DJ, Deakin JFW. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines. Journal of Psychopharmacology 2000; 14: 3–20.
   PubMed Web of Science ®Google Scholar
• Burke WJ, Gergel, Bose A. Fixed dose trial of the single isomer SSRI escitalopram in dpressed outpatients. Journal of Clinical Psychiatry 2002; 63: 331–336.
   PubMed Web of Science ®Google Scholar
• Patris M, Bouchard JM, Bougerol T et al. Citalopram versus fluoxetine: a double- blind, controlled, multicentre, phase III trial in patients with unipolar major depression treated in general practice. International Clinical Psychopharmacology 1996; 11: 129–136.
   Google Scholar
• Bougerol T, Scotto JC, Patris M. Citalopram and fluoxetine in major depression: comparison of two clinical trials in a psychiatrist setting and in general practice. Clinical Drug Investigation 1997; 14: 77–89.
   Web of Science ®Google Scholar
• Silva J. Randomized, double-blind comparison of venlafaxine and fluoxetine in outpatients with major depression [see comments]. Journal of Clinical Psychiatry 1998; 59: 352–357.
   PubMed Web of Science ®Google Scholar
• Rudolph RL, Feiger AD. A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression. Journal of Affective Disorders 1999; 56: 171–181.
   PubMed Web of Science ®Google Scholar
• Dierick M, Ravizza L, Realini R et al. A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients. Progress in Neuropsychopharmacology and Biological Psychiatry 1996; 20: 57–71.
   Google Scholar
• Diaz-Martinez A, Benassinni O, Ontiveros A et al. A randomized, open-label comparison of venlafaxine and fluoxetine in depressed outpatients. Clinical Therapeutics 1998; 20: 467–476.
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Rasmussen JG, Tanghoj P. A 24-week study of 20 mg citalopram, 40 mg citalopram, and placebo in the prevention of relapse of major depression. International Clinical Psychopharmacology 1993; 8: 181–188.
   PubMed Web of Science ®Google Scholar
• Robert P, Montgomery SA. Citalopram in doses of 20-60 mg is effective in depression relapse prevention: a placebo- controlled 6 month study. International Clinical Psychopharmacology 1995; 10 (Suppl. 1): 29–35.
   PubMedGoogle Scholar
• Reimherr FW, Amsterdam JD, Quitkin FM et al. Optimal length of continuation therapy in depression: a prospective assessment during long-term fluoxetine treatment. American Journal of Psychiatry 1998; 155: 1247–1253.
   PubMed Web of Science ®Google Scholar
• Entsuah AR, Rudolph RL, Hackett D et al. Efficacy of venlafaxine and placebo during long-term treatment of depression: a pooled analysis of relapse rates. International Clinical Psychopharmacology 1996; 11: 137–145.
   PubMed Web of Science ®Google Scholar
• Posternak MA, Zimmerman M. Switching versus augmentation: a prospective, naturalistic comparison in depressed, treatment-resistant patients. Journal of Clinical Psychiatry 2001; 62: 135–142.
   PubMed Web of Science ®Google Scholar
• Kiloh LG, Andrews G, Neilson M. The long-term outcome of depressive illness. British Journal of Psychiatry 1988; 153: 752–775.
   Google Scholar
• Thornicroft G, Sartorius N. The course and outcome of depression in different cultures: 10-year follow-up of the WHO Collaborative Study on the Assessment of Depressive Disorders. Psychological Medicine 1993; 23: 1023–1032.
   PubMed Web of Science ®Google Scholar
• Angst J, Preisig M. Outcome of a clinical cohort of unipolar, bipolar and schizoaffective patients. Results of a prospective study from 1959 to 1985. Schweiz. Archives of Neurology and Psychiatry 1995; 146: 17–23.
   PubMedGoogle Scholar
• Statistical yearbook of the Social Insurance Institution, Finland 2000. Publication T1:36, Helsinki 2001.
   Google Scholar
• Heikkinen et al. Terveydenhuollon yksikkökustannukset Suomessa vuonna 2000. Stakes Aiheita 23/2001, Helsinki 2001.
   Google Scholar
• Statistics Finland, http://statfin.stat.fi/statweb/
   Google Scholar
• Straton JB, Cronholm P. Are paroxetine, fluoxetine, and sertraline equally effective for depression? Journal of Family Practice 2002; 51: 285.
   PubMedGoogle Scholar
• Kroenke K, West SL, Swindle R et al. Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial. Journal of the American Medical Association 2001; 286: 2947–2955.
   PubMed Web of Science ®Google Scholar
• Palmer CS, Revicki DA, Genduso LA et al. A cost-effectiveness clinical decision analysis model for schizophrenia. American Journal of Managed Care 1998; 4: 345–355.
   PubMed Web of Science ®Google Scholar
• Runeson B, Wasserman D. Management of suicide attempters: what are the routines and the costs? Acta Psychiatrica Scandinavica 1994; 90: 222–228.
   PubMed Web of Science ®Google Scholar